nach oben

Erschienen in:

01.08.2015 | Original Article

VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations

verfasst von: Jong-In Na, Jo-Heon Kim, Hye-Jeong Kim, Hee-Kyung Kim, Kyung-Sub Moon, Ji-Shin Lee, Jae-Hyuk Lee, Kyung-Hwa Lee, Jong-Tae Park

Erschienen in: Virchows Archiv | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The BRAF V600E mutation is a valuable prognostic factor in thyroid carcinoma despite lingering debate. Successful immunohistochemical (IHC) detection of the BRAF V600E mutation using a VE1 antibody was introduced recently. The objective of this study was to verify the usefulness of IHC detection of the BRAF V600E mutation in thyroid carcinoma using the VE1 antibody. IHC detection of BRAF V600E was performed on various thyroid carcinoma subtypes. IHC results were compared with those obtained from real-time polymerase chain reaction (PCR) detection. Discordant cases were re-examined using a direct sequencing method following nested PCR amplification. The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of anaplastic carcinoma cases. The mutation was not detected in patients with follicular carcinoma (0/18) or in medullary carcinoma (0/21). The overall sensitivity and specificity of IHC using the VE1 antibody were 100 and 94 %, respectively, suggesting that molecular-based results were indeterminable in four VE1-positive cases. IHC using the VE1 antibody is a highly sensitive and specific method for BRAF V600E mutation detection and may represent a future replacement for DNA-based molecular tests.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208 PubMedCrossRef

DeLellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94(8):662–669. doi:10.1002/jso.20700 PubMedCrossRef

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214. doi:10.1089/thy.2009.0110 PubMedCrossRef

Sipos JA, Mazzaferri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22(6):395–404. doi:10.1016/j.clon.2010.05.004 CrossRef

Tang KT, Lee CH (2010) BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 73(3):113–128. doi:10.1016/s1726-4901(10)70025-3 PubMedCrossRef

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867PubMedCrossRef

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954. doi:10.1038/nature00766 PubMedCrossRef

Lanzilotta SG, Grammatica L, Paradiso A, Simone G (2007) BRAF in papillary thyroid carcinoma. Cell Oncol 29(4):269–277PubMed

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13(2):455–464. doi:10.1677/erc.1.01086 PubMedCrossRef

10.

Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89–97PubMedCrossRef

11.

Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36(6):844–850. doi:10.1097/PAS.0b013e318246b527 PubMedCrossRef

12.

Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28(7):742–762. doi:10.1210/er.2007-0007 PubMedCrossRef

13.

Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93(10):3943–3949. doi:10.1210/jc.2008-0607 PubMedCrossRef

14.

Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95(9):4197–4205. doi:10.1210/jc.2010-0337 PubMedCrossRef

15.

Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45(5):818–821PubMedCrossRef

16.

Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, Kim SJ, Hwangbo Y, Park S, Cho HD, Oh MH, Yang SH, Kim CJ (2013) BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol 20(3):759–766. doi:10.1245/s10434-012-2494-0 PubMedCrossRef

17.

Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G (2013) BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol 121(6):291–297. doi:10.1002/cncy.21258 PubMedCrossRef

18.

Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F (2012) The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398. doi:10.1210/jc.2012-1775 PubMedCrossRef

19.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O’Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V (2013) Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309(14):1493–1501. doi:10.1001/jama.2013.3190 PubMedCentralPubMedCrossRef

20.

Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, Pelizzo MR, Rugge M, Mantero F, Nacamulli D, Girelli ME, Busnardo B, Mian C (2010) BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol 163(4):659–663. doi:10.1530/eje-10-0290 PubMedCrossRef

21.

Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P (2014) Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 46(6):509–517. doi:10.1097/pat.0000000000000119 PubMedCentralPubMedCrossRef

22.

Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP (2013) Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 44(11):2563–2570. doi:10.1016/j.humpath.2013.06.018 PubMedCrossRef

23.

Ghossein RA, Katabi N, Fagin JA (2013) Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 98(8):E1414–E1421. doi:10.1210/jc.2013-1408 PubMedCrossRef

24.

Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P (2014) Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers. Horm Metab Res 46(5):370–374. doi:10.1055/s-0034-1368700 PubMedCrossRef

25.

Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122(1):11–19. doi:10.1007/s00401-011-0841-z PubMedCrossRef

26.

Bullock M, O’Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ (2012) Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 19(6):779–784. doi:10.1530/erc-12-0239 PubMedCrossRef

27.

Fisher KE, Neill SG, Ehsani L, Caltharp SA, Siddiqui MT, Cohen C (2014) Immunohistochemical investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies. Appl Immunohistochem Mol Morphol 22(8):562–567. doi:10.1097/PAI.0b013e3182a2f75f PubMedCrossRef

28.

Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P (2014) Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 24(5):858–866. doi:10.1089/thy.2013.0302 PubMedCrossRef

29.

Kim YH, Choi SE, Yoon SO, Hong SW (2014) A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma. Hum Pathol 45(7):1483–1488. doi:10.1016/j.humpath.2014.02.025 PubMedCrossRef

30.

Rossi ED, Martini M, Capodimonti S, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G (2014) Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience. Cancer Cytopathol 122(7):527–535. doi:10.1002/cncy.21416 PubMedCrossRef

31.

Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, Patel KN (2013) Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery 154(6):1199–1204. doi:10.1016/j.surg.2013.06.020, discussion 1204–1195PubMedCentralPubMedCrossRef

32.

LiVolsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho-Simoes M, Wenig B, DeLellis RA, Cady B, Mazzaferri EL, Hay I, Fagin JA, Weber AL, Caruso P, Voutilainen PE, Franssila KO, Williams ED, Schneider AB, Nikiforov Y, Rabes HM, Akslen L, Ezzat S, Santoro M, Eng C, Harach HR (2004) Papillary carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours. IARC Press, Geneva, pp 57–66

33.

American Joint Committee on Cancer, (2010) Thyroid. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, vol 41, 7th edn. Springer, New York, pp 87–100CrossRef

34.

Khoo ML, Asa SL, Witterick IJ, Freeman JL (2002) Thyroid calcification and its association with thyroid carcinoma. Head Neck 24(7):651–655. doi:10.1002/hed.10115 PubMedCrossRef

35.

Moskaluk CA, Kern SE (1997) Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. Am J Pathol 150(5):1547–1552PubMedCentralPubMed

36.

Kwak JY, Han KH, Yoon JH, Kim EK, Moon HJ, Kim YL, Park SJ, Choi JR (2012) BRAFV600E mutation testing in fine needle aspirates of thyroid nodules: potential value of real-time PCR. Ann Clin Lab Sci 42(3):258–265PubMed

37.

Pu X, Pan Z, Huang Y, Tian Y, Guo H, Wu L, He X, Chen X, Zhang S, Lin T (2013) Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: biological and clinical implications. Oncol Lett 5(1):249–254. doi:10.3892/ol.2012.963 PubMedCentralPubMed

38.

Janssen CS, Sibbett R, Henriquez FL, McKay IC, Kemp EG, Roberts F (2008) The T1799A point mutation is present in posterior uveal melanoma. Br J Cancer 99(10):1673–1677. doi:10.1038/sj.bjc.6604731 PubMedCentralPubMedCrossRef

39.

McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA (2013) The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology 45(7):637–644. doi:10.1097/pat.0000000000000008 PubMedCrossRef

40.

Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS (2015) Clinicopathologic correlations of the BRAF(V600E) mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Pathol Res Pract 211(2):162–170. doi:10.1016/j.prp.2014.10.005 PubMedCrossRef

41.

Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ (2013) BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 37(10):1592–1602. doi:10.1097/PAS.0b013e31828f233d PubMedCentralPubMedCrossRef

42.

Kim HS, Kim JO, Lee DH, Lee HC, Kim HJ, Kim JH, Jang YS, Lee JM, Kim SY, Kim YS (2011) Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma. Oncol Rep 25(6):1639–1644. doi:10.3892/or.2011.1225 PubMed

43.

Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rossle M (2014) Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol 122(1):48–58. doi:10.1002/cncy.21352 PubMedCrossRef

44.

Puxeddu E, Durante C, Avenia N, Filetti S, Russo D (2008) Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19(4):138–145. doi:10.1016/j.tem.2007.12.003 PubMedCrossRef

45.

Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12(2):245–262. doi:10.1677/erc.1.0978 PubMedCrossRef

46.

Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123(2):223–233. doi:10.1007/s00401-011-0887-y PubMedCrossRef

47.

de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A, Tallini G (2014) High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. J Clin Endocrinol Metab 99(8):E1530–E1538. doi:10.1210/jc.2013-4389 PubMedCrossRef

48.

Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P (2010) Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 17(17):1839–1850PubMedCrossRef

49.

Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, Berti P, Materazzi G, Miccoli P, Santoro M, Basolo F (2007) The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 92(9):3511–3516. doi:10.1210/jc.2007-0594 PubMedCrossRef

50.

Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A (2011) Aggressive variants of papillary thyroid carcinoma. Head Neck 33(7):1052–1059. doi:10.1002/hed.21494 PubMedCrossRef

51.

Min HS, Lee C, Jung KC (2013) Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci 28(4):534–541. doi:10.3346/jkms.2013.28.4.534 PubMedCentralPubMedCrossRef

52.

Chen JH, Faquin WC, Lloyd RV, Nose V (2011) Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol 24(5):739–749. doi:10.1038/modpathol.2011.2 PubMedCrossRef

53.

Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW (2007) Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 20(7):779–787. doi:10.1038/modpathol.3800797 PubMedCrossRef

54.

Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399–5404. doi:10.1210/jc.2003-030838 PubMedCrossRef

55.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X (2005) Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103(11):2261–2268. doi:10.1002/cncr.21073 PubMedCrossRef

56.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365. doi:10.1016/s0140-6736(12)60868-x PubMedCrossRef

57.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/NEJMoa1103782 PubMedCentralPubMedCrossRef

Titel: VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations
verfasst von: Jong-In Na
Jo-Heon Kim
Hye-Jeong Kim
Hee-Kyung Kim
Kyung-Sub Moon
Ji-Shin Lee
Jae-Hyuk Lee
Kyung-Hwa Lee
Jong-Tae Park
Publikationsdatum: 01.08.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 2/2015
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-015-1773-0

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Springer Medizin

VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease

HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide

The immune response in cancer: from immunology to pathology to immunotherapy

The early stages of tumor angiogenesis in human osteosarcoma: a nude mice xenotransplant model

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

In this issue

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie